CervoMed Inc. - Common Stock CRVO 深 滬
已收盤 12-24 16:00:00 美东时间
8.48
+0.060
+0.71%
華盛通- 最 高8.55
- 今 開8.55
- 成交量 2.09万股
- 最 低 8.21
- 昨 收 8.42
- 總市值 7846.29万
- 52周最高 16.94
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.92
- 委 比 90.48%
- 總股本 925.27万
- 歷史最高 17437.50
- 量 比 0.30
- 振 幅 4.04%
- 歷史最低 1.80
- 每 手 1
- 風險率 2.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
12-19 10:15
Cantor Fitzgerald Initiates Coverage On CervoMed with Overweight Rating
Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on CervoMed (NASDAQ:CRVO) with a Overweight rating.
12-18 21:02
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.
12-18 20:07
CervoMed Shared New Data From Phase 2B RewinD-LB Trial Demonstrating Neflamapimod Treatment Led To A Significant Reduction In Neurodegeneration Biomarker Plasma
1st of two presentations with results from Phase 2b study of neflamapimod at the 18th Clinical Trials on Alzheimer's Disease (CTAD) ConferenceData demonstrates neflamapimod treatment led to significant reductions in
12-02 20:08
CervoMed's Neflamapimod, Oral, Small Molecule, Targeting Critical Disease Processes Underlying Degenerative Disorders Of Brain, To Be Featured In Two Presentations At CTAD 2025
Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLBNew data demonstrating the utility of
11-24 20:10
CervoMed Q3 EPS $(0.84) Misses $(0.49) Estimate, Sales $322.569K Miss $1.300M Estimate
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.49) by 72.13 percent. This is a 52.73 percent decrease over losses of $(0.55) per share from the
11-10 20:21
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
D. Boral Capital Maintains Buy on CervoMed, Maintains $31 Price Target
D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $31 price target.
11-04 21:41
CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
CervoMed Inc. announced the appointment of David Quigley to its Board of Directors. Quigley, a former Senior Partner at McKinsey & Company, has extensive experience in life sciences and private equity. His加入 will support CervoMed as it prepares for Phase 3 trials and commercialization of neflamapimod, a potential treatment for Dementia with Lewy bodies (DLB). Quigley's expertise will help advance the company's clinical and business development go...
10-28 12:00
